About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 588 record(s)
Req # A-2016-001556
All briefing materials provided to the Minister of Health regarding Apotex Inc., AA Pharma, and/or the drug Mefloquine also known under the brand name Lariam from November 1, 2015 and January 13, 2017.Organization: Health Canada
December 2021
Req # A-2020-000769
The name of the manufacturer of the LAP-BAND Adjustable Gastric Banding (LAGB) System (License No. 12197) medical device as of the device's first issuance date September 20, 1999.Organization: Health Canada
December 2021
Req # A-2020-000770
A copy of the Medical Device License of the LAP-BAND Adjustable Gastric Banding (LAGB) System (License No. 12197) medical device as of the device's first issuance date September 20, 1999.Organization: Health Canada
December 2021
Req # A-2021-000924
Copies of the "Section 3: Shipment Details" of every "Application for Permit to Import Cannabis for Medical or Scientific Purposes" approved in 2020 and 2021.Organization: Health Canada
December 2021
Req # A-2021-001190
A report from Health Canada's Medical Device Directorate which includes a list of active/conditional that have Class II Medical licenses which are classified as Software as a Medical Device (SaMD) from Canadian Manufacturers excluding, where possible, SaMD where hardware is also being used. From January 1, 2017 to November 22, 2021.Organization: Health Canada
December 2021
Req # A-2021-001249
Most recent version of the integrated business plan, performance measurement framework/result report and recruitment and staffing strategies from FY2021/2022 at the branch level only for the following branches: Pest Management Regulatory Agency, Controlled Substances and Cannabis Branch, Healthy Environments and Consumer Safety Branch, Regulatory Operations and Enforcement Branch, and Health Products and Food Branch.Organization: Health Canada
December 2021
Req # A-2021-001323
Total number of Clinical Trial Applications (CTA) involving the drug name "psilocybin" for the period between Q1 2017 and Q4 2021 Nationwide and or by province and territory. Total number of exemptions issued by Health Canada under Subsection 56(1) of the Controlled Drugs and Substances Act (CDSA) involving: patient access to psilocybin, practitioner access to psilocybin and pharmacist access to psilocybin for the period between Q1 2017 and Q4 2021 Nationwide and or by province and territory.Organization: Health Canada
December 2021
Req # A-2021-001364
Statistical tables of drug losses reported to Health Canada for loss identification, loss date, provincial code, drug name, generic name, quantity, unit code, loss description and facility type from January 1, 2017 to September 30, 2021.Organization: Health Canada
December 2021
Req # A-2021-001381
The number of fatal adverse drug reactions reported to Health Canada between January 1, 2016 and Oct 30, 2021, in which mood stabilizers are the primary suspect.Organization: Health Canada
December 2021
Req # A-2021-001382
The number of fatal adverse drug reactions reported to Health Canada between January 1, 2016 and Oct 30, 2021, in which antipsychotic drugs are the primary suspect.Organization: Health Canada
December 2021